top of page

ROS1ders Blog

Articles and Resources for ROS1+ Patients, Families, and Health Professionals.

Search

ROS1 fusions, ROS1+ cancer, and entrectinib

Jul 25, 20232 min read

ROS1 fusions, ROS1+ cancer, and entrectinib

Why Did My TKI Stop Working? Targeted Therapy and Acquired Resistance

Mar 8, 20233 min read

Why Did My TKI Stop Working? Targeted Therapy and Acquired Resistance

What is Entrectinib (Rozlytrek)? How it Works, Side Effects and More

Nov 9, 20223 min read

What is Entrectinib (Rozlytrek)? How it Works, Side Effects and More

What is Targeted Therapy?

Sep 21, 20223 min read

What is Targeted Therapy?

Confused about 1st and 2nd line drugs? Here’s a guide!

Dec 29, 20192 min read

Confused about 1st and 2nd line drugs? Here’s a guide!

The ROS1ders Interview Dr. Ross Camidge

Janet Freeman-Daily

May 15, 20191 min read

The ROS1ders Interview Dr. Ross Camidge

pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC

Janet Freeman-Daily

May 4, 20191 min read

pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC

ROS1 News From Europe

Bärbel Söhlke

Apr 15, 20192 min read

ROS1 News From Europe

Entrectinib granted priority review for ROS1 NSCLC and NTRK solid tumors

Janet Freeman-Daily

Feb 18, 20191 min read

Entrectinib granted priority review for ROS1 NSCLC and NTRK solid tumors

Thinking about a “drug vacation” from crizotinib? Read this first!

Janet Freeman-Daily

Jan 16, 20193 min read

Thinking about a “drug vacation” from crizotinib? Read this first!

Crizotinib approved for ROS1 in Australia

Janet Freeman-Daily

Dec 30, 20181 min read

Crizotinib approved for ROS1 in Australia

NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC

Janet Freeman-Daily

Dec 13, 20181 min read

NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC

U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC

Janet Freeman-Daily

Nov 4, 20181 min read

U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC

Crizotinib may be effective again after chemo

Janet Freeman-Daily

Aug 26, 20181 min read

Crizotinib may be effective again after chemo

TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TP

Janet Freeman-Daily

Jun 14, 20181 min read

TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TP

Patients’ Tips on How to Deal with Common Side Effects of Crizotinib (aka Xalkori)

Jan 4, 20174 min read

Patients’ Tips on How to Deal with Common Side Effects of Crizotinib (aka Xalkori)

bottom of page